Immunotherapeutic agents play an increasingly important role in the treatment of B-cell malignancies. CD19 and CD20 are common targets for lymphoid malignancies, though patients who relapse have few therapeutic options remaining. CD22 is a cell surface sialoglycoprotein uniquely present on B-cells and regulates B-cell function and proliferation. Thus, it is an appealing therapeutic target for autoimmune disorders and B-cell malignancies. A variety of therapies targeting CD22 have been developed, including monoclonal antibodies, antibody-drug conjugates, radioimmunoconjugates, chimeric antigen receptor T cells, and bispecific antibodies. Here, we review the biology of CD22 and key therapies targeting CD22 in lymphoid malignancies.
CITATION STYLE
Shah, N. N., & Sokol, L. (2021). Targeting CD22 for the treatment of B-cell malignancies. ImmunoTargets and Therapy. Dove Medical Press Ltd. https://doi.org/10.2147/ITT.S288546
Mendeley helps you to discover research relevant for your work.